CBD Data Events 
LifeCannMD
MAY 27, 2025
Now, with 1.5mg of a balanced THC:CBD tincture twice daily, he’s giving presentations at work and actually enjoying social events again. After six months of microdosing marijuana (2mg THC + 2mg CBD twice daily), his pain went from an 8/10 to a 3/10, and he’s back to playing golf three times a week.
The Cannigma
SEPTEMBER 28, 2023
1 When we invited Cannigma readers to try Slumber’s Deep Zzzs gummies for sleep, we were particularly interested in digging into the data on sleep quality – not just total sleep time. 2 While the data collection effort did not include a control group, the prime findings were found to be statistically significant.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. E-commerce sales of CBD in the U.S. Consumers spent roughly $31.3
The Blunt Truth
MARCH 10, 2020
CBD continues to flourish in the markets despite lack of federal regulations, and we’ve identified some significant events that indicate there’s no sign it’s stopping. Topical CBD Pain-Relief Receives FDA Product Listing Certification. This certification is the first of its kind for a topical OTC drug containing CBD.
SpeedWeed
JULY 18, 2021
percent CBD, and another group smoked weed that had over 20 percent THC content but no CBD. A third group vaped cannabis concentrates with over 60 percent THC content and around 2 percent CBD content, and a fourth group stayed stone cold sober. One group used cannabis flower with at least 20 percent THC content and over 0.7
Cannabis Law Report
JULY 27, 2021
and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS
Cannabis Law Report
JULY 7, 2021
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
Expert insights. Personalized for you.
Let's personalize your content